"In the same space, Anavex (AVXL) targets sigma-1 receptor with two candidates, 2-73 and 3-71. There is some impressive data for a sub-group of patients who has been on 2-73 for over four years without symptom deterioration. More importantly, 2-73 has been in a registration trial for AD for over two years and most likely is ahead of SAVA three years."
"We project AVXL to be in the $40~45 range per share within a year with positive Rett result, partially positive result from Parkinson trial (positive only for those patients with certain genetic markers) and the completion of recruitment for AD trial."
[Reference]
